Actively Recruiting
Effect of CoQ10 on the Outcome of MAFLD Patients
Led by Ain Shams University · Updated on 2025-03-26
60
Participants Needed
1
Research Sites
108 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
So far there has been no universal treatment for MAFLD since it has a complex etiology that involves ethnic, genetic, metabolic and environmental factors. However, therapeutic life changes including: diet, weight loss, and physical activity remain the cornerstone of treatment and is recommended by both American and European associations. Inflammatory biomarkers, such as tumor necrosis factor-alpha, and adipokines play key roles in the pathogenesis of MAFLD, hence, the anti-inflammatory and antioxidant effects of coenzyme Q10 especially at high doses that have not been tested are hypothesized to have a beneficial role in improving the systemic inflammation and biochemical variables. This study is conducted to test this hypothesis
CONDITIONS
Official Title
Effect of CoQ10 on the Outcome of MAFLD Patients
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Adults older than 18 years
- Diagnosed with metabolic dysfunction-associated fatty liver disease (MAFLD) based on having at least three of five metabolic dysregulation criteria
- Waist circumference 63; 102 cm for men and 63; 88 cm for women
- HDL cholesterol less than 40 mg/dl in men or less than 50 mg/dl in women or on specific drug therapy
- Plasma triglycerides 63; 150 mg/dl or on specific drug therapy
- Blood pressure 63; 130/85 mmHg or on specific anti-hypertensive therapy
- Fasting blood glucose 63; 100 mg/dl or on specific anti-hyperglycemic therapy
- Elevated serum transaminases 1 to 4 times the upper limit of normal
- Imaging evidence of fatty liver by pelviabdominal ultrasound and Fibro-CAP study
- Willing to sign informed consent and comply with study procedures and follow-up
You will not qualify if you...
- Pregnancy or lactating
- Physical or mental abnormalities
- Hepatitis C virus (HCV) infection
- Hepatitis B virus (HBV) infection
- Anemia
- Thrombocytopenia
- Hematological malignancies
- Ongoing alcoholism (more than 30g/day for men, more than 20g/day for women)
- Renal failure
- Autoimmune hepatitis
- Celiac disease
- Wilson's disease
- Hemochromatosis
- Use of certain drugs: Tamoxifen, Valproic acid, Amiodarone, Methotrexate, Steroids, Anticoagulants, All anti-oxidative stress agents, Contraceptives, Intrauterine devices
- Chronic use of systemic immunosuppressive agents or drugs affecting liver profile
- Hypothyroidism or hyperthyroidism
- History of bypass surgeries
- Receiving total parenteral nutrition (TPN)
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
National Hepatology and tropical medicine research institute
Cairo, Egypt
Actively Recruiting
Research Team
M
Mariam Seif
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here